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Abstract
Background: Strongyloidiasis is commonly a clinically unapparent, chronic infection, but immuno suppressed
subjects can develop fatal disease. We carried out a review of literature on hyperinfection syndrome (HS) and
disseminated strongyloidiasis (DS), in order to describe the most challenging aspects of severe strongyloidiasis.
Methods: We conducted a structured search using PubMed to collect case reports and short case series on HS/DS
published from 1991 to 2011. We restricted search to papers in English, Spanish, Italian and French. Case reports
were classified as HS/DS according to given definitions.
Results: Records screened were 821, and 311 were excluded through titles and abstract evaluation. Of 510 full-text
articles assessed for eligibility, 213 were included in qualitative analysis. As some of them were short case series,
eventually the number of cases analyzed was 244.
Steroids represented the main trigger predisposing to HS and DS (67% cases): they were mostly administered to
treat underlying conditions (e.g. lymphomas, rheumatic diseases). However, sometimes steroids were empirically
prescribed to treat signs and symptoms caused by unsuspected/unrecognized strongyloidiasis. Diagnosis was
obtained by microscopy examination in 100% cases, while serology was done in a few cases (6.5%). Only in 3/29
cases of solid organ/bone marrow transplantation there is mention of pre-transplant serological screening.
Therapeutic regimens were different in terms of drugs selection and combination, administration route and
duration. Similar fatality rate was observed between patients with DS (68.5%) and HS (60%).
Conclusions: Proper screening (which must include serology) is mandatory in high - risk patients, for instance
candidates to immunosuppressive medications, currently or previously living in endemic countries. In some cases,
presumptive treatment might be justified. Ivermectin is the gold standard for treatment, although the optimal
dosage is not clearly defined in case of HS/DS.
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Background
Strongyloidiasis is a neglected condition caused by
Strongyloides stercoralis, a soil – transmitted helminth
mainly diffused in tropical and subtropical regions, but
also present in small areas of low endemicity in temper-
ate climates [1]. Most infected individuals are asymp-
tomatic or may present intermittent symptoms, mostly
affecting intestine (from mild abdominal pain, intermit-
tent or persistent diarrhea to more severe conditions
that can mimic inflammatory bowel disease), lungs
(cough, wheezing and asthma, chronic bronchitis) and
skin (pruritus, rash). Systemic symptoms such as weight
loss and cachexia may also occur [2]. Immune suppres-
sed subjects tend to develop hyperinfection syndrome
(HS) and disseminated strongyloidiasis (DS), that are po-
tentially fatal [3]. Therefore, it is mandatory to diagnose
and treat the chronic infection, in order to prevent the
life-threatening form. Unfortunately, the index of suspi-
cion of health care providers seems to be low, especially
in non-endemic countries [4]. Moreover, there are still
gaps in knowledge regarding many aspects of the infec-
tion, such as diagnosis and treatment response [2].
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Our aim was to systematically review case reports of
severe strongyloidiasis, in order to outline the main fea-
tures of hyperinfection and disseminated strongyloidiasis
and the difficulties in their management.
Methods
We carried out a systematic review of case reports/short
case series published in PubMed from January 1991 to
April 2011. We considered papers available in the follo-
wing languages: English, Spanish, Italian, French.
The electronic search strategy was as follows: disease
(strongyl*, anguillulose) AND severity of cases (disse-
minat*, hyperinfect*, severe, death, fatal, mortality) OR
disease (strongyl*, anguillulose) AND associated con-
ditions (tumor*, cancer, haematolog*, lymphom*, leukem*,
leukaem*, neoplas*, malignan*, HTLV*, HIV, AIDS, hy-
pogammaglobulinemia, rheumat*, “biological agents”,
diabet*, transplant*, COPD, steroid*, glucocorticoid*, Im-
munosuppression [MeSH], Immunocompromised Host
[MeSH]) and limiting the search to humans. Search was
done on March 20th 2011.
Definitions used for case - inclusion [5]: - Dissemina-
tion: larvae found in any organ, other than the respirato-
ry and the gastrointestinal tracts. Hyperinfection: infection
confined to lungs and gastrointestinal tract, but signs/
symptoms of severe diseases in relation to elevated
number of larvae; in particular, necessity of intensive
care, presence of sepsis/meningitis by enteric bacteria,
death (without any other clear underlying cause).
Results
Data synthesis
Our search strategy permitted to identify 821 papers, of
which 311 were excluded by title and abstract evalu-
ation. Full-text papers were then assessed for eligibility
according to the criteria outlined above. Among the 213
papers included, some were small case series, eventually
the number of cases analyzed was 244 (Figure 1).
Countries
Reports from highly endemic countries were 65/244
(27%), with India ([6–23]), Argentina ([24–28]), Brazil
([29–39]) and Peru ([40,41,42]) accounting for more
than two thirds. Only four cases were reported from the
whole of Africa [43–46], three of which in South Africa,
a state where adequate diagnostic facilities are available.
We collected 83/244 (34%) reports from North America
(USA [47–109] and Canada [110–116]), 58/244 (24%)
from Europe (Belgium [40,117], France [118–129],
Germany [130,131], Greece [132–134], Italy [135–141],
the Netherlands [142–145], Spain [146–155], Switzerland
[156], UK [157–164]) and five (2%) from Oceania
Figure 1 PRISMA flow chart: data collection and selection of studies.
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(Australia [165–168] and New Zealand [169]). In these
areas of low/no endemicity, half of the patients were
immigrants (70/146, 48%), while a few subjects were
veterans (5/146, 3%) who presumably acquired the in-
fection during military service in an endemic country.
Other areas of low endemicity where cases have been
reported are in Eastern Asia (21 cases, mostly from
Japan ([170–177]) and Taiwan ([178–182])), the Arabian
peninsula (nine cases, mostly from Kuwait ([183,184])
and Qatar ([185,186])) and Israel ([187,188]) (three cases).
Countries such as Iran ([189]), Turkey ([190]) and
Venezuela ([191]) that might be presumed at medium to
high prevalence, account for only one case each.
Triggers for development of HS/DS
According to the case definitions, 171 cases were classi-
fied as hyper infection and 73 cases as dissemination.
A high percentage of patients (67%: 164/244) were
under corticosteroids: most of them presented clinical
conditions causing immune suppression per-se or due to
other related therapies (for instance leukemia, rheumatic
conditions, transplant), as it is shown in Table 1. On the
other hand, a few patients were taking steroids for eosino-
philia and/or a specific symptoms caused by S. stercoralis
itself (data reported in Table 1 too). A patient even under-
went bone marrow transplant because of an unexplained
eosinophilia misdiagnosed as “idiopathic hypereosinophilic
syndrome” [81]; after receiving steroids and immunosup-
pressive therapy he developed HS (but only limited aut-
opsy was performed, so we cannot rule out DS) and died.
Transplant is surely an event that poses the Strongy-
loides - infected patient at high risk of developing HS/DS.
We collected 28/244 (11.5%) cases of HS/DS in transplant
patients, of whom 19 (68%) died. A couple of patients
who developed hyper infection also had co infection with
CMV [21,107]. All the surviving patients received
ivermectin, either as single treatment (1 patient) or in
combination with albendazole (7) or thiabendazole (1)
[29,54,60,71,90,92,94,142,145,150].
HTLV-1 infection is a well known risk factor (some-
times in association with related haematological ma-
lignancies), of which we found 24/244 (10%) reports
([214,158,120,159,215,53,54,143,122,12,111,32,216,77,126,
163,114,80,35,164,175,155,116]). Ten of the 24 patients
(42%) died. One patient had HTLV-1-HIV co infection
[122]; he developed an E. coli meningitis but successfully
responded to ivermectin, two doses given some days
(not specified how many) apart.
We found 38/244 (15%) reports on HIV-positive pa-
tients, 26 (68%) of whom died (Figure 2). Seven HIV
patients were also receiving steroids for suspected Pneu-
mocystis jiroveci pneumonia [24,26], immune recons-
titution inflammatory syndrome [105], misdiagnosis of
asthma [58], Wegener granulomatosis [36], toxoplasmo-
sis encephalitis [36], cerebral TB with vasculitis [124];
six of them died.
A few reports/case series describe severe strongyloid-
iasis in patients with alcoholism [178,217] and malnutri-
tion [27,171]. An apparently immunocompetent patient
developed hyper infection and died two days after having
started therapy with thiabendazole [149]. Unfortunately
autopsy was denied.
Diagnosis
Eosinophilia was present in 55/244 cases (22.5%) overall,
and only in 12/73 cases (16.4%) of dissemination. In all
cases S. stercoralis was found at microscopy examination
of biological samples. Serology was performed only in
Table 1 Patients under steroid treatment: reasons for prescription
Condition N (%) References
COPD/asthma/lung fibrosis 30 (18.3) [48,49,52,57-59,68,99,101,118,121,123,128,137,146,153,180-183,185,187,188,192-196]
Leukemia/lymphoma 13 (7.9) [9,17,23,25,37,47,56,98,111,126,162,186]
SLE 9 (5.5) [41,64,66,86,151,176,197,198]
Rheumatoid arthtritis 4 (2.4) [83,103,199,200]
IBD 6 (3.6) [59,147,148,164,177,201]
Sarcoidosis 2 (1.2) [65,132]
Cancer 8 (4.8) [30,54,93,97,112,160,169,202]
Organ/bone marrow transplant 25 (15.2) [21,25,29,31,39,48,51,54,60,70,71,74,76,81,87,88,90,92,94,142,145,150,184]
Glomerulonephritis/CRI 6 (3.6) [16,18,20,129,130,154]
“Idiopatic” eosinophilia 3 (1.8) [7]
Multiple myeloma/myelodisplasia 6 (3.6) [72,185,203-206]
Aspecific symptoms 2 (1.2) [85,166]
Other clinical conditions 46 (28) [17,22,34,36,54,59,66,84,89,100,102,110,113,124,125,127,133-135,140,155,159,171-174,207-213]
HIV-related opportunistic infections/IRIS 4 (2.4) [24,26,36,105]
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16/244 patients (6.5%) (Table 2). In a couple of organ
transplant recipients, an ELISA test was negative pre-
transplant, but resulted positive in the deceased donors
(test performed retrospectively) [60,145]. In other two
cases serology (ELISA) was negative: a HIV-infected per-
son, who had larvae in stool and sputum [165] and a
patient with dermatomyositis, under chronic treatment
with prednisone and methotrexate, who died from dis-
seminated strongyloidiasis (larvae found at autopsy in
skin, lungs, small and large bowel, gall bladder, vessels of
meninges and cervical spinal cord) [100].
Diagnosis was obtained post mortem in 29 cases
(12%).
Therapy
Therapies given were very different in relation to the
drugs used and the length of treatment.
In Table 3 we summarize the drugs used. In
the “other drugs” group we found mebendazole
[9,17,44,48,131,137,181,218], cambendazole [35,36],
levamisole [43,199], pyrantel pamoate [75,108], die-
thylcarbamazine [14].
Albendazole was used as a single drug even in recent
case reports; since 2008 we found patients treated with
albendazole only in reports from Pakistan [203], Romania
[217], Taiwan [182], Israel [187], Kuwait [184], Argentina
[25], Malaysia [207], Greece [133], Thailand [208].
In most cases the administration route was oral, but
due to severe clinical conditions of patients, administra-
tion via nasogastric tube, subcutaneous injection (veter-
inary formulation) and retention enema were used, too.
A patient who developed disseminated strongyloidiasis
after an empiric steroid treatment for pruritic rash was
treated with albendazole [166]. Only one dose could be
given, as the patient died. After his death, a review of his
clinical records showed that he had been previously
diagnosed with strongyloidiasis and treated with a 3-day
course of albendazole; although serology persisted posi-
tive and eosinophilia was still present 6 and 12 months
after treatment, the patient did not receive any further
therapy. Another patient who died from Strongyloides
hyper infection had never been treated previously, des-
pite a positive serology [101].
Outcome
The recorded deaths were 153/244 (62.7%). A similar
fatality rate was observed in patients with dissemin-
ation (50/73 = 68.5%) and with hyperinfection (102/
171 = 60%).
All 42 of 244 patients who did not receive any therapy
died. Excluding patients treated with combination ther-
apy, we observe that 25/34 (73%) patients treated with
albendazole died, while deaths among patients treated
with ivermectin and thiabendazole were 18/38 (47%) and
28/55 (51%), respectively.
Discussion
Considering that a considerable number of case re-
ports are described in non endemic countries, we as-
sume that fatal cases must be quite frequent in endemic
countries, although they are not frequently published in
the literature.
The main risk factors identified in this review have
been reported previously, in particular steroids are fre-
quently the trigger for developing severe strongyloidiasis.
Unfortunately it was not possible to extract from the
case reports the cumulative dosage and the duration of
the corticosteroids treatment. Although the association
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Figure 2 Deaths in the HIV patients subgroup.
Table 2 Patients tested with serology: chronic conditions
and corticosteroids therapy
Year Chronic condition Corticosteroids Serology Ref.
1991 polychondritis Yes positive [89]
1994 COPD Yes positive [57]
1996 HIV No negative [165]
2001 none Yes positive [166]
2004 bronchogenic carcinoma Yes positive [160]
2004 none Yes positive [183]
2005 multiple myeloma Yes positive [72]
2005 multiple myeloma Yes positive [204]
2005 nephrotic syndrome No positive [204]
2007 nephrotic syndrome Yes positive [139]
2008 none Yes positive [144]
2008 asthma Yes positive [101]
2009 heart transplant Yes negative [145]
2009 lung transplant Yes positive [92]
2010 dermatomyositis Yes negative [100]
2011 renal transplant Yes negative [60]
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reporting cases of patients under steroids who had not
been previously screened for strongyloidiasis. Moreover,
we found papers reporting severe strongyloidiasis in
patients who were previously diagnosed with the infec-
tion but had not received a proper treatment. Once
more, the lack of familiarity with strongyloidiasis by health
care providers is the weak link in the chain; this is also
highlighted by the fact that in 12% of cases the diagnosis
was made post mortem. Eosinophil count is often normal
in severe strongyloidiasis, hence this test has a limited ex-
cluding power.
Serology was not frequently performed. In fact, in case
of hyperinfection and dissemination the diagnosis is eas-
ily made by direct examination of the biological samples.
Serology would be most useful in chronic infections, be-
fore hyperinfection and/or dissemination occur, while in
patients who are already immune suppressed its sensitiv-
ity is probably lower.
Limits in our results are due to incomplete informa-
tion in the case descriptions. Moreover, cases in which
autopsy was not performed sometimes couldn’t allow a
proper classification. Actually, in the 65 cases we classi-
fied as hyper infections, autopsy was not done, hence it
is not possible to rule out dissemination. Moreover, we
found the same fatality rate for patients with hyper in-
fection and with dissemination, but a misclassification
might have played a role. In fact, we think that from a
clinical, practical point of view the distinction between
hyper infection and dissemination is not essential, be-
cause they’re both severe conditions requiring immedi-
ate assessment and care.
In general, the best drug to treat strongyloidiasis is
ivermectin which is effective and well tolerated.
There are still some concerns about the treatment
schedule of the chronic infection, and this is even
more debated in case of hyper infection/dissemin-
ation. In fact there are no specific guidelines and the
case reports we collected outline a Babylon of differ-
ent therapeutic schemes. Subcutaneous ivermectin
(veterinary formulation) has been used on an em-
piric basis, when intestinal absorption is decreased
or the patient cannot swallow tablets. On the other
hand, albendazole is still used even as a single drug,
although it has been proved to be poorly effective.
In some cases, this might be due to the scarce avail-
ability of ivermectin in many countries.
Conclusions
The first step to be done to guarantee an adequate
management of infected patients is to avoid a de-
layed diagnosis. Unfortunately, lack of familiarity with
strongyloidiasis by health care providers still seems
to be the main cause of delay. A better diffusion of
the available information is badly needed, and collab-
oration among different specialists (oncologists, rheuma-
tologists. . .) is desirable in order to provide common and
adequate protocols for screening and treatment of at –
risk patients.
It is mandatory to treat patients in the chronic phase,
before HS/DS develop. Patients with possible, previous
exposure to the parasite should be screened with ser-
ology before corticosteroid treatment, chemotherapy or
transplant. Considering the high tolerability of ivermec-
tin, it would be probably worth treating high – risk
patients irrespective of the result of the screening test, in
order to avoid the potential consequences of a possible
false negative result.
Ivermectin is currently the gold standard for treatment
of strongyloidiasis, so it is simply no more ethical to use
any other drug. Moreover, ivermectin is in the WHO
model lists of essential medicines [219], so it should be
registered and made available everywhere, particularly in
endemic countries.
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